Acadia Pharmaceuticals   Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: San Diego CA United States (1993)

Organization Overview

First Clinical Trial
2004
NCT00087542
First Marketed Drug
2016
pimavanserin (nuplazid)
First NDA Approval
2016
pimavanserin (nuplazid)
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ACADIA Pharmaceuticals Inc. | ACADIA PHARMS INC

Active Ingredients

Marketed Drugs (2)

pimavanserin (nuplazid) (2016 NDA)

trofinetide (Daybue) (2023 NDA)

Drugs in Phase 4 Trials (1)

pimavanserin (nuplazid) (33 trials)

Drugs in Phase 3 Trials (3)

acp-204 (1 trial)

carbetocin (Pabal) (1 trial)

trofinetide (Daybue) (4 trials)

Drugs in Phase 2 Trials (3)

Key: Acadia Pharmaceuticals (2) Acquired (1)

acp-104 (2 trials)

ct-044 (4 trials)

quetiapine (seroquel) (1 trial)

Indications

Approved Indications


 

Parkinson Disease

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 2)

Alzheimer Disease (Phase 2)

Dementia (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Hallucinations (Phase 2)

Mental Disorders (Phase 4)

Neurodegenerative Diseases (Phase 3)

Parkinson Disease (Phase 4)

Psychomotor Agitation (Phase 2)

Psychotic Disorders (Phase 4)

Rett Syndrome (Phase 3)

Schizophrenia (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 45
  • # of Trial APIs: 7